Potential prognostic biomarkers in acute myeloid leukemia (AML) can be identified by understanding the cellular pathway and molecular changes underlying leukemogenesis. Deregulation of apoptosis is one of the important features of AML and to understand the molecular mechanism underlying apoptosis and its contribution to tumor progression, this study aimed to evaluate anti-apoptotic Bcl2 protein expression in AML and correlate with FLT3 parameters for their role in prognosis of disease.
Acute myeloid leukemia (AML) is a highly heterogenous disease [1, 2] and despite recent progress in molecular genetics, the understanding of mechanisms underlying the leukemic growth and response to treatment is limited [2] . This has lead to lack of efficient biomarkers in clinical diagnosis in AML. Biomarkers are required to enable identification of patients who are most likely to benefit from specific treatments and to help improve clinical outcome and treatment design [3] . Potential therapeutic targets and prognostic biomarkers of AML patients can be identified by understanding the cellular pathways and molecular changes involved in malignant transformation.
Apoptosis plays key role in the control of tissue homeostasis, such as rapidly renewing hematopoietic tissue [4] and deregulation of apoptosis may give rise to neoplastic transformation. Several lines of evidence indicate that leukemic cells undergo apoptosis in response to chemotherapy, suggesting an association between therapy-induced apoptosis and therapeutic efficacy in AML [5] . Abnormalities in the apoptotic pathway give survival advantage to the leukemic cells and thereby play major role in development of drug resistance [4] .
Major regulators of apoptotic pathway are Bcl2 (B cell lymphoma 2) family of proteins. Some of these proteins (Bcl2, Bcl-XL) are anti-apoptotic while others (Bad, Bax, Bid) are pro-apoptotic. The sensitivity of cells to apoptotic stimuli can depend on the balance of pro-and anti-apoptotic Bcl2 proteins [6] . In AML, Bcl2 overexpression is linked with resistance to chemotherapy and short survival [7, 8] . Therefore, detection of Bcl2 protein expression in AML is appealing as a potential prognostic biomarker.
The present study evaluated Bcl2 protein expression in de novo AML, myelodysplastic syndrome (MDS) and aplastic anemia patients. Further, the protein expression was correlated with clinical and haematologic parameters, disease status and treatment offered along with Fms-like tyrosine kinase-3 (FLT3) mutation status, mRNA and FLT3 protein expression in AML patients. The diagnosis and classification of the acute leukemia samples were based on morphology and cytochemistry according to the French-American-British (FAB) classification and by immunophenotyping as per the criteria of the European Group for the Immunological Characterization of Leukemias [9] . The patients' detailed clinical history was noted from the case files maintained at the Medical Record Department of the Institute. This study was approved by the Institutional Scientific Review Board and Ethics Committee. Patients provided informed consent to use their sample for the study.
Patients and methods

Patients
Therapy. Out of 144 AML patients enrolled in the study, 76 patients underwent treatment while 68 patients were either lost to follow up or died within a month. Disease remission was achieved in 30% (23/76) while disease relapse was noted in 70% (53/76) of AML patients. The treatment protocols were decided by clinicians of the Institute. Adult AML non-M3 patients were treated with 7+3 protocol, pediatric AML non-M3 patients were treated with Berlin Frankfurt Munster (BFM) 93 and AML M3 patients were treated with All Trans Retinoic Acid (ATRA) and / or Arsenic trioxide in combination with anthracycline. Oral chemotherapy was given to 17 patients. Detailed treatment protocol has been described earlier [10] .
Flow cytometry analysis. Surface and cytoplasmic protein expression were studied using bone marrow or peripheral blood samples on intact leukemic blasts by flow cytometric analysis along with immunophenotypic study. The unstained or isotype controls for surface and cytoplasmic antigens were simultaneously stained and CD45 antibody was added in each tube for leukemic blast gating. For the study of cytoplasmic Bcl2 protein expression, 2 ml Lysing solution (1:10 dilution, BD Biosciences) was added to adjusted cell count of 1 x 10 6 mononuclear cells per 100 μl sample and incubated for 15 minutes. Then samples were centrifuged at 400 g for 5 minutes. The supernatant was discarded and 1 ml Perm/ Wash buffer (1:10 dilution, BD Biosciences) was added and incubated for 20 minutes. Then samples were centrifuged at 400 g for 5 minutes and the supernatant was discarded. The monoclonal antibodies fluorescein isothiocyanate (FITC) conjugated anti-Bcl2 (Bcl2/100) along with peridinin-chlorophyll protein (PerCp) conjugated anti-CD45 (2D1) (20 µl each) were added to the pellet and incubated for 15 minutes. Then 2 ml phosphate buffered saline (PBS) was added and the samples were centrifuged at 400 g for 5 minutes. The supernatant was discarded and the pellet was resuspended in 500 µl PBS [11] .
To study the surface FLT3 protein expression, monoclonal antibody phycoerythrin (PE) conjugated anti-FLT3 (4G8) was added along with FITC conjugated anti-CD34 (8G12) and PerCp conjugated CD45 (20 µl each) to 100 μl sample (1 x 10 6 mononuclear cells) and incubated for 15 minutes. After addition of 2 ml Lysing solution (1:10 dilution, BD Biosciences), the samples were incubated for another 15 minutes. Then samples were centrifuged at 400 g for 5 minutes. The supernatant was discarded and the remaining pellet was washed twice with PBS and then resuspended in 500 µl PBS [11] .
For lineage assignment the following combinations of monoclonal antibodies were used as the primary panel: CD22 (S-HCL-1; FITC) / CD34 (8G12; PE) / CD5 (L17F12; Phycoerythrin cyanine 7 (PE-CY7)) / CD10 (HI10a; Allophycocyanin (APC)) / CD19 (SJ25C1; Allophycocyanin cyanine 7 (APC-Cy7)) / CD45, CD7 (4H9; FITC) / CD13 (L138; PE) / CD33 (P67.6; PE-Cy7) / CD117 (104D2; APC) / HLA-DR (L243; APC-Cy7) / CD45, cytoMPO (5B8; FITC) / cytoCD79a (2ST8.5H7; PE) / cytoCD3 (SK7; PE-Cy7) / nTdt (E17-1519; APC) / CD45. All the antibodies and reagents were procured from BD Biosciences (San Jose, USA) and followed the manufacturer's protocol.
Statistical analysis. Statistical analysis was carried out using SPSS statistical software version 17 (SPSS Inc, USA). Pearson's Chi-square test with Pearson's correlation coefficient (r) was used to assess correlation and significance between the two parameters. Univariate survival analysis was carried out by Kaplan and Meier method and Log Rank statistics was used to assess the prognostic significance of disease free survival (DFS) and overall survival (OS). Multivariate survival analysis was performed using Cox regression model with forward stepwise (likelihood ratio) method. The Wald statistics and relative risk [Exp(B)] with 95% confidence interval (CI) for Exp(B) were used to evaluate the prognostic significance. P values ≤ 0.05 were considered significant.
Results
Anti-apoptotic protein Bcl2 expression in acute myeloid leukemia. Bcl2 positivity was noted in 71% (102/144) of AML patients ( Figure 1) .
Correlation of Bcl2 with clinical and hematological parameters. With clinical parameters, a trend of high incidence of Bcl2 positivity was noted in patients of pediatric (<15 years; 79%, 22/28) and younger (15 to 59 years; 72%, 69/96) age groups as compared to older (≥60 years; 55%, 11/20) age group while with gender, similar incidence of Bcl2 positivity was noted (Table 1) .
In relation to AML subtypes, significantly high incidence of Bcl2 positivity was noted in patients with AML M4 (94%, 17/18) as compared to M1 (85%, 23/27), M5a (65%, 11/17), M2 (58%, 21/36), M5b (57%, 8/14) and M3 (50%, 6/12) subtypes (X 2 =18.71, r=+0.02, P=0.01). Both the patients with AML M6 subtype showed Bcl2 positivity (100%, 2/2) while one patient with AML M7 subtype did not show Bcl2 positivity.
With hematological parameters, a trend of high incidence of Bcl2 positivity was noted in patients with high N:C (nuclear: cytoplasmic) ratio (74%, 64/87) as compared to moderate N: C ratio (50%, 5/10) while incidence of Bcl2 positivity showed no significant difference in subgroups of blast count, WBC count, platelet count, RBC count, hemoglobin level, M:E (myeloid:erythroid) ratio and sudan black B stain (cytochemical stain).
Correlation of Bcl2 with CD34 expression and leukemia associated immunophenotype (LAP). Bcl2 protein when correlated with CD34 (Table 2) , significantly high incidence of Bcl2 positivity was noted in CD34+ AML (77%, 67/87; P=0.04) as compared to CD34-AML (61%, 35/57).
Further, Bcl2 when correlated with the myeloid lineage markers (CD13, CD33, CD117 and MPO), significantly high incidence of Bcl2 positivity was noted in CD117+ AML (80%, 86/108; P=0.0001) as compared to CD117-AML (44%, 16/36) while incidence of Bcl2 positivity showed no significant difference in subgroups of CD13, CD33 and MPO.
With non-lineage markers, incidence of Bcl2 positivity showed no significant difference in the subgroups of Tdt and HLA-DR. With respect to aberrant B cell markers, CD19 was expressed in 19% (27/144) of patients whereas CD79a and CD22 were aberrantly expressed in two patients. Incidence of Bcl2 positivity showed no significant difference in the subgroups of CD19. With respect to aberrant T cell markers, CD3 was expressed in 18% (26/144) and CD7 in 14% (19/140) of patients whereas CD2 and CD5 were aberrantly expressed in two and one patient respectively. A trend of high incidence of Bcl2 positivity was noted in CD7+ AML (84%, 16/19) as compared to CD7-AML (69%, 84/121) while showing no significant difference in the subgroups of CD3.
Correlation of Bcl2 protein expression with FLT3 mutation status, FLT3 mRNA transcript and FLT3 protein expression. FLT3 ITD mutations were detected through PCR amplification using mutation specific primers [12] . FLT3 TKD point mutations were detected through RT-PCR followed by restriction enzyme EcoRV digestion. FLT3 ITD mutation to wild type ratio and mRNA transcript levels were calculated based on the quantification of DNA and mRNA. The procedure for detection of these mutations as well as quantification of DNA and mRNA was carried out as described earlier [10] . (Table 3) , with respect to DFS, a trend of high incidence of disease relapse was noted in Bcl2 positive patients (75%, 42/56) as compared to Bcl2 negative patients (55%, 11/20), while with respect to OS, no such trend was observed.
Impact of Bcl2 protein on disease status with respect to FLT3 parameters. Bcl2 negative and positive patients were divided according to FLT3 parameters (Table 3) .
With respect to DFS, Bcl2 negative and positive patients showed no significant correlation with subgroups of FLT3 ITD and FLT3 TKD mutation. With FLT3 mRNA transcript levels, Bcl2 negative patients showed no significant correlation while a trend of high incidence of relapse was noted in Bcl2 positive patients with low FLT3 mRNA transcript level (86%, 24/28) as compared to high FLT3 mRNA transcript level (64%, 16/25). With FLT3 protein subgroups, Bcl2 negative patients showed no significant correlation while significantly high incidence of disease relapse was noted in Bcl2 positive patients with FLT3 With respect to OS, significantly higher incidence of death was noted in Bcl2 negative patients with FLT3 ITD positivity (100%, 3/3; P=0.0001) as compared to FLT3 ITD negativity (32%, 7/22) while no such trend was seen in Bcl2 positive patients. With FLT3 mRNA transcript level, significantly higher incidence of death was noted in Bcl2 negative patients with high mRNA transcript level (55%, 6/11; P=0.03) as compared to low mRNA transcript level (11%, 1/9) while no such trend was noted in Bcl2 positive patients. Bcl2 negativity and positivity showed no significant correlation with subgroups of FLT3 TKD mutation and FLT3 protein.
Impact of Bcl2 positivity on disease status in relation to treatment offered. Bcl2 expression was correlated with treatment offered in 76 patients. In AML non-M3 adult patients treated with 7 + 3 protocol, with respect to DFS, Bcl2 positive patients showed significantly high relapse rate (79%, 26/33; P=0.04) as compared to Bcl2 negative patients (38%, 03/08). While with respect to OS, no significant difference was noted (Table 4A ). In AML non-M3 pediatric patients treated with BFM93 protocol, with respect to DFS, Bcl2 positive patients showed a trend of high relapse rate (57%, 4/7) as compared to Bcl2 negative patients (40%, 2/5). While respect to OS, no significant difference was noted (Table 4B ). In case of AML M3 treated with ATRA / Arsenic trioxide protocol, with respect to DFS, inverse trend was observed wherein Bcl2 positive patients showed a trend of high remission rate (100%, 3/3) as compared to Bcl2 negative patients (33%, 1/3 ). Similarly, with respect to OS, Bcl2 positive patients showed increased incidence of overall survival (100%, 3/3) as compared to Bcl2 negative patients (67%, 2/3) (Table 4C) .
Multivariate survival analysis including all parameters. Multivariate analysis including all clinical and hematological parameters, Bcl2 protein and FLT3 parameters was performed. In case of DFS, high WBC count (>11000/µl) entered at step 1 as significant prognostic factor (Wald statistic=4.390, df=1, Exp(B)=2.02, P=0.03) and Bcl2 positivity (≥20%) (Wald statistic=4.426, df=1, Exp(B)= 2.38, P=0.03) at step 2 for predicting disease relapse, while in case of OS, high blast count (≥61%) was found as significant prognostic factor (Wald statistic=11.478, df=1, Exp(B)=4.80, P=0.001) entered at step 1 for predicting poor OS.
Since, Bcl2 positivity with FLT3 protein positivity showed significantly higher incidence of disease relapse, Bcl2 and FLT3 protein expression were combined to form a new parameter with subgroups of Bcl2-/FLT3 protein-, Bcl2+/FLT3 protein-, Bcl2-/FLT3 protein+ and Bcl2+/FLT3 protein+. It was included with above mentioned parameters in multivariate analysis. In case of DFS, combined Bcl2+/FLT3 protein+ entered at step 1 as significant prognostic factor (Wald statistic=4.792, df=1, Exp(B)=1.67, P=0.02) and high WBC count (>11000/µl) (Wald statistic=4.399, df=1, Exp(B)=2.03, P=0.03) at step 2 for predicting disease relapse while in case of OS, high blast count (≥61%) was found as significant prognostic factor (Wald statistic=11.478, df=1, Exp(B)=4.80, P=0.001) entered at step 1 for predicting poor OS.
Comparison of incidence of Bcl2 protein expression in aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia patients. Incidence of Bcl2 protein in aplastic anemia, MDS and AML patients was evaluated. Bcl2 positivity was found to be similar in MDS (80%, 4/5) and AML (71%, 102/144) patients, however it was significantly high (P=0.0001) as compared to aplastic anemia patients (5%, 1/19).
Discussion
This study evaluated Bcl2 protein by flow cytometry method in AML patients. High incidence of Bcl2 positivity (71%) was noted which was further correlated with conventional hematologic parameters and evaluated for its clinical relevance as well as correlated with the FLT3 mutations, FLT3 mRNA transcript level and FLT3 protein expression.
Incidence of Bcl2 protein in the present study was 71%. The Bcl2 expression in AML has been studied by flow cytometry [5, [14] [15] [16] [17] [18] [19] , western blotting [20] and immnunocytochemistry [13, 21, 22] by various groups reporting heterogenous expression in the range of 34 to 87%. With clinical and hematological pa- Log Rank=1.00, df=1, P=0.31 *P value ≤ 0.05 is significant; DFS, Disease free survival; OS, Overall survival rameters, no significant correlation could be obtained. Present study showed a trend of high incidence of Bcl2 positivity in pediatric and younger age group as compared to older (≥60 years) age group which is contradictory to the known fact that increasing age is associated with accumulation of mutations as well as aberrant protein expression.
Bcl2 positivity was found to be significantly high in AML subtype M4 and M1 followed by M5a, M2, M5b and M3. Both patients with AML M6 expressed Bcl2 positivity. High Bcl2 expression was reported by Venditti et al [18] in AML M0, M1 and M6, and by Campos et al [23] in AML M4 and M5 subtypes. Also, Tzifi et al [24] noted Bcl2 positivity in immature AML subtypes and similarly present study findings show significant positive correlation of Bcl2 with CD34 and CD117. Similarly, Poeta et al [5] observed low bax/bcl2 ratio associated with high CD34 and CD117 levels while, association of Bcl2 with CD34 over expression is supported by other study groups [16] [17] [18] . Further, Bcl2 positivity tended to be high in high N:C ratio, suggesting association of Bcl2 with immature cell type.
In univariate analysis, a trend of association of Bcl2 over expression with reduced DFS and increased incidence of disease relapse was observed whereas no correlation was noted with OS. Similarly, some study groups [16, 21, 23, 24] demonstrated that increased mean fluorescence intensity and high levels of Bcl2 expression significantly lowered the complete remission rates. With respect to treatment options, in case of AML non-M3 patient group, Bcl2 positivity showed high incidence of disease relapse in adult patients treated with 7+3 protocol and pediatric patients treated with BFM93 protocol. This result is in accordance with study by Tamm et al [25] where they noted that childhood AML patients treated with BFM93 protocol and with Bax:Bcl2 ratio above average, had a shorter overall survival. Present study demonstrated high incidence of disease remission in Bcl2 positive patients with ATRA / Arsenic trioxide treatment protocol. This result is supported by some study groups [26] [27] [28] who observed downregulation of Bcl-2 expression after treatment with ATRA in AML patient samples and HL-60 cells.
Bcl2 protein was correlated with FLT3 parameters, where a trend of high incidence of Bcl2 positivity was found with FLT3 protein positivity. Also, when Bcl2 expression in relation to the FLT3 parameters was evaluated for its impact on clinical outcome, FLT3 protein positivity in Bcl2 positive patients showed significantly poor DFS with a high incidence of disease relapse. Similarly, the results of in vitro study by Lisovsky et al [29] demonstrate that stimulation with FLT3-ligand induces proliferation and up-regulates Bcl2. These results suggest that FLT3 protein over expression, irrespective of its mutation status, plays role in sustaining leukemic cell growth by upregulation of Bcl2. Contradictory to the results obtained with DFS, Bcl2 when correlated with OS, Bcl2 negative patients having FLT3 ITD or having high mRNA transcript level showed significantly high incidence of death which suggests that mutation in FLT3 or aberrant expression of FLT3 mRNA downregulated Bcl2 while increasing the aggressiveness of the disease.
In multivariate survival analysis high WBC count and Bcl2 protein expression emerged as significant predictors of high relapse rate and reduced DFS while high blast count was significant predictor of high incidence of death and reduced overall survival. Similarly, Bcl2 has been reported as independent predictive factor of survival by Campos et al [23] , independent prognostic factor for achieving complete remission by Lauria et al [16] and independent prognostic factor for reduced OS and EFS by Kornblau et al [20] . Our findings are consistent with studies by Chang et al [30] and Meshinchi et al [31] demonstrating WBC count as significant prognostic factor while blast count was demonstrated to be of prognostic significance for reduced OS by Amin et al [32] . Also, in multivariate analysis, the subgroup of Bcl2+/FLT3 protein+ emerged as significant prognostic factor followed by high WBC count for predicting poor DFS. As discussed earlier, these results further confirm the parallel role of Bcl2 and FLT3 protein over expression in inhibiting apoptosis and inducing chemoresistance in leukemic blasts.
In aplastic anemia patients, incidence of Bcl2 was 5%. Other studies [33, 34] have shown expression of Bcl2 on CD34+ cells in aplastic anemia but apoptosis in such cases mainly being Fas -dependent, the anti-apoptotic activity of Bcl2 becomes ineffective. In MDS patients, Bcl2 protein over expression was found to be 80%. The protein has been studied by other groups through flow cytometry or immunohistochemistry and found to have heterogenous expression in MDS patients. A study by Kurotaki et al [35] demonstrated high Bcl2 over expression in RAEB-t subtypes and suggested that apoptosis was suppressed in late events of MDS.
In summary, incidence of anti apoptotic protein Bcl2 was high in AML suggesting suppression of apoptotic pathway. Its positivity was significantly associated with immature myeloblasts. Further, patients with Bcl2 positivity and FLT3 protein positivity showed significantly reduced DFS suggesting the parallel role of these proteins in imparting chemoresistance to the leukemic cells.
